Detail akcie Geron Corp online

Business Summary: Geron Corporation is a commercial-stage biopharmaceutical company. The Company develops first-in-class telomerase inhibitor, RYTELO (imetelstat) for the treatment of adult patients with low- to intermediate-1 risk myelodysplastic syndromes (lower-risk MDS), with transfusion-dependent (TD) anemia requiring four or more red blood cell units over eight weeks who have not responded to or have lost response to or are ineligible for erythropoiesis-stimulating agents (ESAs). RYTELO is supported by the high unmet need in lower-risk MDS, including the observed benefit of RYTELO in difficult-to-treat subpopulations, such as patients with high transfusion burden and ring sideroblast negative (RS-) patients. It is also engaged in conducting a pivotal Phase III clinical trial of imetelstat in JAK-inhibitor relapsed/refractory myelofibrosis (R/R MF), as well as studies in other myeloid hematologic malignancies.
Financial Summary: BRIEF: For the fiscal year ended 31 December 2024, Geron Corp revenues increased from $237K to $77M. Net loss decreased 5% to $174.6M. Revenues reflect Development of Therapeutical products segment increase from $237K to $499K. Lower net loss reflects Development of Therapeutical products segment loss decrease of 10% to $173.7M. Basic Earnings per Share excluding Extraordinary Items increased from -$0.32 to -$0.27.